Modern low-molecular-weight heparins in the prevention and treatment of venous thromboembolic complications in oncourologic patients

Abstract

Oncourologic diseases are accompanied by a risk for subsequent venous thromboembolic complications, which are rated the most dangerous in terms of thrombogenic effect. The article presents a review of the clinical studies of efficacy and safety, and the experience in using of modern low-molecular-weight heparins in clinical practice - drugs of choice for the prevention of venous thromboembolic complications in cancer patients. Particular attention is paid to Bemiparin - a new second-generation low-molecular-weight heparin with a significant antithrombotic effect and improved pharmacological parameters that allow it to be successfully used in patients with impaired renal function in oncourological practice.

Keywords

• venous thromboembolic complications
• oncological patients
• oncourological diseases
• prevention
• low-molecular-weight heparins
• bemiparin
• efficacy
• safety